2 reports of this reaction
1.3% of all OATMEAL reports
#18 most reported adverse reaction
APPLICATION SITE VESICLES is the #18 most commonly reported adverse reaction for OATMEAL, manufactured by Kenvue Brands LLC. There are 2 FDA adverse event reports linking OATMEAL to APPLICATION SITE VESICLES. This represents approximately 1.3% of all 160 adverse event reports for this drug.
Patients taking OATMEAL who experience application site vesicles should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE VESICLES is a less commonly reported adverse event for OATMEAL, but still significant enough to appear in the safety profile.
In addition to application site vesicles, the following adverse reactions have been reported for OATMEAL:
The following drugs have also been linked to application site vesicles in FDA adverse event reports:
APPLICATION SITE VESICLES has been reported as an adverse event in 2 FDA reports for OATMEAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE VESICLES accounts for approximately 1.3% of all adverse event reports for OATMEAL, making it a notable side effect.
If you experience application site vesicles while taking OATMEAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.